Aphaia Pharma

R&D

At LSX 2025, editor-in-chief Jonah Comstock connected with Dr Steffen Sebastian-Bolz, chief science officer at Aphaia Pharma.

News

Merck's drug for tumours associated with rare disease neurofibromatosis type 1, Ezmekly, has been cleared for NHS use in children as young as two.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.